Aptose Biosciences (NASDAQ:APTO) PT Lowered to $40.00 at Royal Bank of Canada

Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) had its price target lowered by Royal Bank of Canada from $75.00 to $40.00 in a research report report published on Wednesday, The Fly reports. Several other research analysts have also weighed in on the stock. StockNews.com began coverage on shares of Aptose Biosciences in a research note […]

Related Keywords

Toronto ,Ontario ,Canada ,Aptose Biosciences ,Piper Sandler ,Sequoia Financial Advisors ,Annandale Capital ,Aptose Biosciences Inc ,Aptose Biosciences Company Profile ,Renaissance Technologies ,Sigma Planning Corp ,Canaccord Genuity Group ,Toronto Dominion Bank ,Royal Bank ,Get Rating ,Genuity Group ,Financial Advisors ,Dominion Bank ,Planning Corp ,Biosciences Inc ,Aptose Biosciences Daily ,Nasdaq Apto ,Dapto ,Medical ,Lower Price Target ,Royal Bank Of Canada ,